Supplemental References

S1. Mehta, S.H., Cox, A., Hoover, D.R., Wang, X.H., Mao, Q., Ray, S., Strathdee, S.A., Vlahov, D., and Thomas, D.L. 2002. Protection against persistence of hepatitis C. *Lancet* 359:S228-S233.

S2. Lai, M.E., Mazzoleni, A.P., Argiolu, F., De Virgilis, S., Balestrieri, A., Purcell, R.H., Cao, A., and Farci, P. 1994. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. *Lancet* 343:388-390.

S3. Prince, A.M., Brotman, B., Huima, T., Pascual, D., Jaffery, M., and Inchauspe, G. 1992. Immunity in hepatitis C infection. *J Infect Dis* 165:438-443.

S4. Bukh, J., Thimme, R., Meunier, J.C., Faulk, K., Spangenberg, H.C., Chang, K.M., Satterfield, W., Chisari, F.V., and Purcell, R.H. 2008. Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. *J Virol* 82:8183-8195.

S5. Folgori, A., Capone, S., Ruggeri, L., Meola, A., Sporeno, E., Ercole, B.B., Pezzanera, M., Tafi, R., Arcuri, M., Fattori, E., et al. 2006. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. *Nat Med* 12:190-197.

S6. Rollier, C., Depla, E., Drexhage, J.A., Verschoor, E.J., Verstrepen, B.E., Fatmi, A., Brinster, C., Fournillier, A., Whelan, J.A., Whelan, M., et al. 2004. Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response. *J Virol* 78:187-196.

S7. Youn, J.W., Park, S.H., Lavillette, D., Cosset, F.L., Yang, S.H., Lee, C.G., Jin, H.T., Kim, C.M., Shata, M.T., Lee, D.H., et al. 2005. Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. *Hepatology* 42:S179-S186.

S8. Schofield, D.J., Bartosch, B., Shimizu, Y.K., Allander, T., Alter, H.J., Emerson, S.U., Cosset, F.L., and Purcell, R.H. 2005. Human monoclonal antibodies that

react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity. *Hepatology* 42:1055-1062.

S9. Farci, P., Shimoda, A., Wong, D., Cabezon, T., De Gioannis, D., Strazzera, A., Shimizu, Y., Shapiro, M., Alter, H.J., and Purcell, R.H. 1996. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. *Proc Natl Acad Sci U S A* 93:15394-15399.

S10. Forns, X., Payette, P.J., Ma, X., Satterfield, W., Eder, G., Mushahwar, I.K., Govindarajan, S., Davis, H.L., Emerson, S.U., Purcell, R.H., et al. 2000. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. *Hepatology* 32:618-625.

S11. Meuleman, P., Hesselgesser, J., Paulson, M., Vanwolleghem, T., Desombere, I., Reiser, H., and Leroux-Roels, G. 2008. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. *Hepatology* 48:1761-1768.

S12. Timpe, J.M., Stamataki, Z., Jennings, A., Hu, K., Farquhar, M.J., Harris, H.J., Schwarz, A., Desombere, I., Roels, G.L., Balfe, P., et al. 2008. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. *Hepatology* 47:17-24.

S13. Feld, J.J., and Hoofnagle, J.H. 2005. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. *Nature* 436:967-972.

S14. Welker, M.W., and Zeuzem, S. 2009. Occult hepatitis C: how convincing are the current data? *Hepatology* 49:665-675.

S15. Golden-Mason, L., Klarquist, J., Wahed, A.S., and Rosen, H.R. 2008. Cutting edge: programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences. *J Immunol* 180:3637-3641.

S16. Pilli, M., Zerbini, A., Penna, A., Orlandini, A., Lukasiewicz, E., Pawlotsky, J.M., Zeuzem, S., Schalm, S.W., von Wagner, M., Germanidis, G., et al. 2007. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). *Gastroenterology* S8:1S7-1S18.

S17. Lauer, G.M., Lucas, M., Timm, J., Ouchi, K., Kim, A.Y., Day, C.L., Schulze Zur Wiesch, J., Paranhos-Baccala, G., Sheridan, I., Casson, D.R., et al. 2005. Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. *J Virol* 79:S479-S488.

S18. Badr, G., Bedard, N., Abdel-Hakeem, M.S., Trautmann, L., Willems, B., Villeneuve, J.P., Haddad, E.K., Sekaly, R.P., Bruneau, J., and Shoukry, N.H. 2008. Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells. *J Virol* 82:10017-10031.

S19. Thompson, A., Patel, K., Tillman, H., and McHutchison, J.G. 2009. Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges. *J Hepatol* 50:184-194.

S20. Kuntzen, T., Timm, J., Berical, A., Lennon, N., Berlin, A.M., Young, S.K., Lee, B., Heckerman, D., Carlson, J., Reyor, L.L., et al. 2008. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. *Hepatology* 48:1769-1778.

S21. Gaudieri, S., Rauch, A., Pfafferott, K., Barnes, E., Cheng, W., McCaughan, G., Shackel, N., Jeffrey, G.P., Mollison, L., Baker, R., et al. 2009. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. *Hepatology* 49:1069-1082.

S22. Liang, Y., Ishida, H., Lenz, O., Lin, T.I., Nyanguile, O., Simmen, K., Pyles, R.B., Bourne, N., Yi, M., Li, K., et al. 2008. Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors. *Gastroenterology* S10:1710-1718 e1712.

S23. Rehermann, B., and Nascimbeni, M. 2005. Immunology of hepatitis B virus and hepatitis C virus infection. *Nat Rev Immunol* 5:215-229.

S24. Heller, T., and Rehermann, B. 2005. Acute hepatitis C: a multifaceted disease. *Semin Liver Dis* 25:7-17.